Nov. 1 (Bloomberg) -- Israel’s TA-25 Index declined the most since Oct. 4, dropping 2.8 percent to 1,102.07 at the 4:30 p.m. close in Tel Aviv. Investors traded about 1.38 billion shekels ($377 million) of shares and convertible securities, according to bourse data.
The following stocks rose or fell today. Symbols are in parentheses.
AudioCodes Ltd. (AUDC IT) tumbled the most in almost a month, retreating 11 percent to 11.59 shekels. The maker of Internet telephony equipment reported a third-quarter loss of $527,000 after a profit of $2.9 million a year earlier.
Bezeq Israeli Telecommunication Corp. (BEZQ IT) declined the most since Oct. 2, slumping 4.1 percent to 7.41 shekels. Clal Finance Brokerage Ltd. cut its share-price estimate on the country’s largest fixed-line phone company to 8.3 shekels from 9.4 shekels.
Brainsway Ltd. (BRIN IT) rose for the first time in three days, jumping 3.8 percent to 20.68 shekels. The maker of devices to treat neurological disorders received U.S. Food and Drug Administration approval to begin a multicenter trial to test the efficacy of its Deep TMS device to treat bipolar disorder.
Koor Industries Ltd. (KOR IT), the owner of 26.2 million shares of Credit Suisse Group AG as of Aug. 14, declined the most since Sept. 11, slumping 5.7 percent to 42 shekels. Switzerland’s second-biggest bank reported third-quarter earnings that missed analysts’ estimates. Koor’s controlling shareholder Discount Investment Corp. (DISI IT) lost 4.9 percent to 36.67 shekels.
Micronet Ltd. (MCRNL IT) soared the most in two years, surging 22 percent to 1.413 shekels. The manufacturer of mobile- data collection products received a 20 million-shekel follow-on order from a U.S. client.
Nova Measuring Instruments Ltd. (NVMI IT) slid the most since Oct. 2, dropping 4.8 percent to 25.82 shekels. The developer of monitoring and measurement systems for the semiconductor industry said third-quarter net income fell to $5.9 million from $7.3 million a year earlier.
Teva Pharmaceutical Industries Ltd. (TEVA IT) retreated the most since Oct. 9, declining 1.7 percent to 146 shekels. Harel Finance Ltd. cut its share-price estimate for the world’s largest generic drugmaker to 200 shekels from 247 shekels. The company is scheduled to report third-quarter results tomorrow.
--Editors: Susan Lerner, Tim Farrand
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org